Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A and C polysaccharide vaccine
- Development stage
- Unknown
- Lead developer
- Yuxi Watson Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The meningococcal group A and C polysaccharide vaccine is a bivalent vaccine developed by Yuxi Watson Biotechnology (a subsidiary of Walvax Biotechnology) for the prevention of epidemic cerebrospinal meningitis caused by *Neisseria meningitidis* serogroups A and C. It consists of purified capsular polysaccharides from these two serogroups. Upon administration, the vaccine induces the production of serogroup-specific bactericidal antibodies, which provide protection against invasive meningococcal disease. Unlike conjugate vaccines, polysaccharide vaccines do not typically induce T-cell dependent immunity or long-term immunological memory in young children, and are primarily used in older children and adults or for outbreak control in specific populations.
- Other names
- Meningococcal A+C Polysaccharide VaccineMPSV-ACBivalent meningococcal polysaccharide vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)TT (Tetanus toxoid)
Beyond the preview
Go deeper on meningococcal group A and C polysaccharide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A and C polysaccharide vaccine.